Full history for every metric is available with a Kvantra account
Jeisys Medical Inc. (287410.KQ)
Key financial summary
Financials in KRW| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | KRW bn | - | - | 48 | 81 | 117 | 143 | 168 |
| Operating profit | KRW bn | 36 | 38 | |||||
| Net profit | KRW bn | - | - | 8 | 14 | 27 | 25 | 28 |
| EPS reported | KRW | 322.0 | 360.8 | |||||
| Operating cashflow per share | KRW | 432.2 | 432.2 | |||||
| Capex per share | KRW | 198.6 | 198.6 | |||||
| FCF per share | KRW | 233.6 | 233.6 | |||||
| Free cash flow | KRW bn | 18 | 10 | |||||
| Net debt | KRW bn | -26 | -12 | |||||
| Book value equity | KRW bn | 95 | 111 | |||||
| Book value per share | KRW | 1,234 | 1,446 | |||||
| Number of shares | m | 77.02 | 77.05 | |||||
| DPS (TTM paid) | KRW | 0.00 | 0.00 |
Financial summary
Financials in KRW| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 32.58 | - | |||||
| P/B LTM | x | 8.38 | 8.75 | |||||
| P/S LTM | x | 5.57 | 5.81 | |||||
| P/FCF LTM | x | 45.08 | 95.04 | |||||
| EV/EBITDA LTM | x | 19.33 | 15.31 | |||||
| EV/Sales LTM | x | 5.40 | 5.73 | |||||
| Earnings Yield LTM | % | 3.07% | 2.54% | |||||
| FCF Yield | % | 2.22% | 1.05% | |||||
| Quality | ||||||||
| ROE | % | 26.10% | 28.44% | |||||
| ROIC | % | 21.03% | 21.03% | |||||
| Operating margin | % | 25.39% | 25.39% | |||||
| Gross margin | % | 69.20% | 69.20% | |||||
| FCF/Sales | % | 12.35% | 12.35% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | -12.97% | +5.58% | |||||
| Sales Growth YoY | % | +22.72% | +34.57% | |||||
| Net Income Growth YoY | % | -8.59% | +7.34% | |||||
| FCF Growth | % | +50.44% | -59.71% | |||||
| Operating Profit Growth | % | +6.69% | +13.35% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.69 | 0.15 | |||||
| Net Debt/EBITDA | x | -0.58 | -0.58 | |||||
| EBIT/Net interest | x | 163.25 | 163.25 | |||||
| Net debt/market cap | % | -3.25% | -1.27% | |||||
| Net debt/Equity | x | -0.27 | -0.11 | |||||
| Gross debt/equity | x | 0.27 | 0.63 | |||||
Company overview
Jeisys Medical Inc. is a company dedicated to the innovation and production of medical equipment, catering to a range of healthcare professionals including plastic surgeons, dermatologists, and other clinicians. Operating from its headquarters in Seoul, South Korea, the firm serves both its domestic market and international clients. Its comprehensive product line addresses various aesthetic and dermatological concerns, offering solutions for skin revitalization, firming, pigment correction, fat reduction, acne treatment, tattoo removal, and the management of scars and stretch marks. These advanced systems are branded under names such as ULTRAcel Q+, Cellec V, LIPOcel, AcGen, TRI-BEAM Premium, Edge ONE, SmoothCool, and ULTRAcel. The company distributes its offerings through an extensive network of partners. Jeisys Medical Inc. was established in 2001.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Jeisys Medical Inc. (287410.KQ)
Jeisys Medical Inc. is a company dedicated to the innovation and production of medical equipment, catering to a range of healthcare professionals including plastic surgeons, dermatologists, and other clinicians. Operating from its headquarters in Seoul, South Korea, the firm serves both its domestic market and international clients. Its comprehensive product line addresses various aesthetic and dermatological concerns, offering solutions for skin revitalization, firming, pigment correction, fat reduction, acne treatment, tattoo removal, and the management of scars and stretch marks. These advanced systems are branded under names such as ULTRAcel Q+, Cellec V, LIPOcel, AcGen, TRI-BEAM Premium, Edge ONE, SmoothCool, and ULTRAcel. The company distributes its offerings through an extensive network of partners. Jeisys Medical Inc. was established in 2001.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free